Table 2.
Multivariate Analysis of Posttreatment Alteration of Peripheral Lymphocyte Subsets and Clinical Efficacy in Patients With COVID-19 Pneumonia
| Multivariate Analysisa | ||||
|---|---|---|---|---|
| Posttreatment Alteration | No. (%) | P Value | Odds Ratio | 95% CI |
| Total lymphocyte decrease | 17 (36) | .071 | 0.113 | .011–1.209 |
| CD3+CD4+ T-cell decrease | 16 (29) | .056 | 0.157 | .024–1.047 |
| CD3+CD8+ T-cell decrease | 16 (29) | .011 | 0.056 | .006–.516 |
| CD4+/CD8+ ratio increase | 30 (56) | .032 | 0.099 | .012–.821 |
| CD19+ B-cell decrease | 14 (25) | .010 | 0.033 | .002–.439 |
| CD16+CD56+ NK-cell decrease | 32 (59) | .190 | 0.310 | .054–1.787 |
Abbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019.
aAdjusted by age, sex, disease severity on admission, oxygen inhalation, antiviral treatment, and use of corticosteroid and immune enhancer.